Relief Therapeutics
Z├╝rich
About Relief Therapeutics
Relief focuses primarily on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications. Its lead drug candidate RLF-100TM (aviptadil) is being investigated in two placebo-controlled U.S. late-stage clinical trials in respiratory deficiency due to COVID-19. Relief holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $98.2M
- Funding stage: IPO
- Last round: Post-IPO Debt (Aug 2024)
- Ticker: otcqb:RLFTF
- Website: relieftherapeutics.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/relief-therapeutics-25335 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.